The Technical Analyst
Cara Therapeutics Inc [CARA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Cara Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-4.03% $0.679
America/New_York / 24 apr 2024 @ 12:53
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 37.09 mill |
| EPS: | -2.19 |
| P/E: | -0.310 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 54.66 mill |
| Avg Daily Volume: | 0.647 mill |
| RATING 2024-04-23 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.310 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.05x |
| Company: PE -0.310 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.574 - 0.784 ( +/- 15.47%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-05 | Goncalves Joana | Sell | 2 753 | Common Stock |
| 2024-04-05 | Terrillion Scott | Sell | 2 753 | Common Stock |
| 2024-02-29 | Terrillion Scott | Sell | 3 293 | Common Stock |
| 2024-02-29 | Posner Christopher | Sell | 5 834 | Common Stock |
| 2024-02-29 | Goncalves Joana | Sell | 3 293 | Common Stock |
| INSIDER POWER |
|---|
| 72.15 |
| Last 96 transactions |
| Buy: 1 992 546 | Sell: 375 720 |
Forecast:
14:38 - $0.669
Live Trading Signals (every 1 min)
Forecast
1: 13:08 - $0.685
Forecast 2: 13:58 - $0.666
Forecast 3: 14:38 - $0.669
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.679 (-4.03% ) |
| Volume | 0.118 mill |
| Avg. Vol. | 0.647 mill |
| % of Avg. Vol | 18.16 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CARA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CARA
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Latest Press Releases
2024-04-02 07:00:00 - Press Release
Cara Therapeutics To Present At The 23rd Annual Needham Virtual Healthcare Conference
Stamford, conn., april 02, 2024 (globe newswire) -- cara therapeutics, inc. (nasdaq: cara), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that christopher posner, president and chief executive officer, will present at the 23rd annual needham virtual healthcare conference on tuesday, april 9, 2024, at 8:40 a.m. edt.
2024-03-07 07:00:00 - Press Release
Cara Therapeutics To Host Notalgia Paresthetica (np) Virtual Kol Event On Wednesday, March 27, 2024
Stamford, conn., march 07, 2024 (globe newswire) -- cara therapeutics, inc. (nasdaq: cara), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the company will host a virtual key opinion leader (kol) event titled “meet the np experts” on wednesday, march 27, 2024, at 10:00 a.m. edt.
2024-03-04 16:01:00 - Press Release
Cara Therapeutics Announces Fourth Quarter And Full Year 2023 Financial Results
–announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (np)–
2024-02-12 16:01:00 - Press Release
Cara Therapeutics To Announce Fourth Quarter And Full Year 2023 Financial Results On March 4, 2024
Stamford, conn., feb. 12, 2024 (globe newswire) -- cara therapeutics, inc. (nasdaq: cara) today announced the company will host a conference call and live audio webcast on monday, march 4, 2024, at 4:30 p.m. est to report fourth quarter and full year 2023 financial results and provide a corporate update.
2024-01-22 07:00:00 - Press Release
Cara Therapeutics Prioritizes Late-stage Notalgia Paresthetica Program And Extends Cash Runway Into 2026
– focus on phase 2/3 program in notalgia paresthetica (np), a neuropathic disorder with significant unmet need –
Latest News
2024-04-02 09:02:14 - MarijuanaStocks
Cara Therapeutics, Inc. (CARA) to Present at the 23rd Annual Needham Virtual Healthcare Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 8:40 a.m. EDT.
2024-04-02 07:00:00 - GlobeNewsWire
Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
STAMFORD, Conn., April 02, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 8:40 a.m. EDT.
2024-03-04 19:07:09 - Seeking Alpha
Cara Therapeutics, Inc. (CARA) Q4 2023 Earnings Call Transcript
Cara Therapeutics, Inc. (NASDAQ:CARA ) Q4 2023 Earnings Call Transcript March 4, 2024 4:30 PM ET Company Participants Matt Murphy - Manager, IR Chris Posner - CEO Ryan Maynard - CFO Joana Goncalves - CMO Conference Call Participants Annabel Samimy - Stifel Joseph Stringer - Needham & Company Dennis Ding - Jefferies David Amsellem - Piper Sandler Operator Thank you for standing by, and welcome to Cara Therapeutics Fourth Quarter and Full Year 2023 Earnings Conference Call. At this time all participants are in a listen-only mode.
2024-03-04 18:11:03 - Zacks Investment Research
Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates
Cara Therapeutics (CARA) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.56 per share a year ago.
2024-02-25 13:37:41 - InvestorPlace
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum.
2024-02-12 16:01:00 - GlobeNewsWire
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:30 p.m. EST to report fourth quarter and full year 2023 financial results and provide a corporate update.
2023-12-19 13:32:14 - Zacks Investment Research
CARA's Late-Stage Skin Disease Study Fails, Stock Plummets 49%
CARA discontinues the clinical program of oral difelikefalin for pruritus associated with atopic dermatitis following the failure of dose-finding Part A of the late-stage study. Stock plunges 49%.
2023-11-13 19:32:27 - Zacks Investment Research
Cara (CARA) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Cara (CARA) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
2023-10-23 07:00:00 - GlobeNewsWire
Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023
STAMFORD, Conn., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, November 13, 2023, at 4:30 p.m. ET to report third quarter 2023 financial results and provide a corporate update.
2023-08-07 18:54:47 - Zacks Investment Research
Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates
Cara Therapeutics (CARA) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.08 per share a year ago.